1. Home
  2. CELZ vs PHGE Comparison

CELZ vs PHGE Comparison

Compare CELZ & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Creative Medical Technology Holdings Inc.

CELZ

Creative Medical Technology Holdings Inc.

HOLD

Current Price

$1.88

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$6.99

Market Cap

7.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CELZ
PHGE
Founded
1998
2015
Country
United States
United States
Employees
N/A
57
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
7.0M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
CELZ
PHGE
Price
$1.88
$6.99
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
20.0K
82.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
1.33
N/A
EPS
N/A
N/A
Revenue
$11,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.22
N/A
52 Week Low
$1.50
$0.25
52 Week High
$6.25
$8.50

Technical Indicators

Market Signals
Indicator
CELZ
PHGE
Relative Strength Index (RSI) 45.89 62.96
Support Level $1.72 $0.41
Resistance Level $1.96 $8.50
Average True Range (ATR) 0.08 0.78
MACD 0.01 0.08
Stochastic Oscillator 47.62 84.59

Price Performance

Historical Comparison
CELZ
PHGE

About CELZ Creative Medical Technology Holdings Inc.

Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: